AR016431A1 - Derivados de piperidina, un proceso para su preparacion, medicamentos que los comprenden y el uso de dichos derivados para la manufactura de un medicamento - Google Patents
Derivados de piperidina, un proceso para su preparacion, medicamentos que los comprenden y el uso de dichos derivados para la manufactura de un medicamentoInfo
- Publication number
- AR016431A1 AR016431A1 ARP980106249A ARP980106249A AR016431A1 AR 016431 A1 AR016431 A1 AR 016431A1 AR P980106249 A ARP980106249 A AR P980106249A AR P980106249 A ARP980106249 A AR P980106249A AR 016431 A1 AR016431 A1 AR 016431A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- disorders
- hydrogen
- manufacture
- preparation
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 150000003053 piperidines Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000027796 Blood pressure disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000013200 Stress disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 150000008043 acidic salts Chemical class 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000004872 arterial blood pressure Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 108010020615 nociceptin receptor Proteins 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Derivados de piperidina, que comprenden compuestos de la formula (I) donde: X es -O- o -CH2-; Y es -C(O)-, -(CH2)n o -N(CH3); n es 1 o 2, o X e Y juntosson -CH=CH-; Z es -NH-, -CH2, -O- o =CH-; A1 es un grupo de formula (a) o (b); B es -(CH2)m; m es0, 1 o 2; R1 y R2 son cada uno independientemente hidrogeno oalquilo C1-6 lineal o ramificado; R3 es hidrogeno o halogeno; R4 es hidrogeno o hidroxi y la línea de puntos es un grupo -CH2-CH2 opcional y a las sales deadicion ácida farmacéuticamente aceptables de los mismos. Los compuestos son antagonistas del receptor OFQ. En consecuencia, los mismos serán utiles en eltratamiento de la memoria y la atencion, los trastornos psiquiátricos, neurologicos y fisiologicos, especialmente, sin que esto sea limitativo, en el alivio delos síntomas de la ansiedad y de los trastornos del estrés, la depresion, la pérdida de la memoria debido al mal de Alzheimer o demás demencias, epilepsia yconvulsiones, estados agudos y/o cronicos de dolor, síntomas de retiro de drogas adictivas, control del equilibrio del agua, trastornos de presion sanguíneaarterial y excrecion de Na+ y trastornos metabolicos, tal como obesidad. Además se describe un proceso para su preparacion, un medicamento que los comprende yel uso de los mismos derivados de piperidina para la manufactura de un medicamento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97121844 | 1997-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016431A1 true AR016431A1 (es) | 2001-07-04 |
Family
ID=8227781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106249A AR016431A1 (es) | 1997-12-11 | 1998-12-09 | Derivados de piperidina, un proceso para su preparacion, medicamentos que los comprenden y el uso de dichos derivados para la manufactura de un medicamento |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6166209A (es) |
| EP (1) | EP1037892B1 (es) |
| JP (1) | JP3453121B2 (es) |
| KR (1) | KR100369689B1 (es) |
| CN (1) | CN1112365C (es) |
| AR (1) | AR016431A1 (es) |
| AT (1) | ATE278695T1 (es) |
| AU (1) | AU744192B2 (es) |
| BR (1) | BR9813543A (es) |
| CA (1) | CA2310458C (es) |
| DE (1) | DE69826891T2 (es) |
| ES (1) | ES2229557T3 (es) |
| PT (1) | PT1037892E (es) |
| TR (1) | TR200001669T2 (es) |
| WO (1) | WO1999029696A1 (es) |
| ZA (1) | ZA9811345B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6462053B1 (en) | 1999-08-20 | 2002-10-08 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
| TWI279402B (en) * | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| US6803372B2 (en) | 1999-08-20 | 2004-10-12 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
| JP2003524634A (ja) | 1999-12-06 | 2003-08-19 | ユーロ−セルティーク，エス．エイ． | ノシセプチン受容体親和性を有するベンズイミダゾール化合物 |
| US6686370B2 (en) | 1999-12-06 | 2004-02-03 | Euro-Celtique S.A. | Triazospiro compounds having nociceptin receptor affinity |
| EP1244437A4 (en) | 1999-12-06 | 2005-02-09 | Euro Celtique Sa | TERTIARY AMINO COMPOUNDS HAVING AFFINITY FOR OPIOID RECEPTOR |
| WO2001060796A1 (en) * | 2000-02-18 | 2001-08-23 | Meiji Seika Kaisha, Ltd. | PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID δ RECEPTOR AGONISTS |
| MXPA03009602A (es) | 2001-04-18 | 2004-04-02 | Euro Celtique Sa | Analogos de nociceptina. |
| HUP0401109A3 (en) | 2001-04-18 | 2007-12-28 | Euro Celtique Sa | Nociceptin analogs, their use and pharmaceutical compositions containing them |
| HUP0401333A3 (en) | 2001-04-18 | 2004-11-29 | Euro Celtique Sa | Spiropyrazole compounds and pharmaceutical compositions containing them |
| PT1385518E (pt) | 2001-04-18 | 2008-10-07 | Euro Celtique Sa | Compostos de benzimidazolona |
| WO2002085354A1 (en) * | 2001-04-18 | 2002-10-31 | Euro-Celtique S.A. | Spiroindene and spiroindane compounds |
| WO2002088089A1 (fr) * | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales |
| WO2002094825A1 (fr) * | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de spiropiperidine |
| US20030078278A1 (en) * | 2001-06-26 | 2003-04-24 | Pfizer Inc. | Spiropiperidine compounds as ligands for ORL-1 receptor |
| PT1491212E (pt) | 2002-03-29 | 2012-11-16 | Mitsubishi Tanabe Pharma Corp | Medicamento para distúrbios de sono |
| WO2005060947A2 (en) * | 2003-12-19 | 2005-07-07 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
| JPWO2005085228A1 (ja) * | 2004-03-05 | 2008-01-17 | 萬有製薬株式会社 | シクロアルカノピリジン誘導体 |
| US8076349B2 (en) | 2004-12-09 | 2011-12-13 | Virochem Pharma Inc. | Spirotropane compounds and methods for the modulation of chemokine receptor activity |
| JP2008522986A (ja) * | 2004-12-09 | 2008-07-03 | ヴァイロケム・ファーマ・インコーポレーテッド | 新規スピロトロパン化合物およびケモカイン受容体活性を調節するための方法 |
| EP1896479A1 (en) * | 2005-06-17 | 2008-03-12 | Pfizer, Inc. | Alpha-(aryl-or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists |
| EP1943250A1 (en) | 2005-09-09 | 2008-07-16 | Euro-Celtique S.A. | Fused and spirocycle compounds and the use thereof |
| EP1987009A1 (en) * | 2006-01-30 | 2008-11-05 | Euro-Celtique S.A. | Cyclourea compounds as calcium channel blockers |
| RU2009119394A (ru) | 2006-12-07 | 2011-01-20 | Ф. Хоффманн-Ля Рош Аг (Ch) | Производные спиро-пиперидина в качестве антагонистов рецептора v1a |
| BRPI0721138A2 (pt) | 2006-12-22 | 2014-04-01 | Hoffmann La Roche | Derivados de espiro-piperidina |
| AU2007338116B2 (en) | 2006-12-22 | 2012-04-26 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives |
| US8728275B2 (en) | 2012-07-27 | 2014-05-20 | Ecolab Usa Inc. | Glycerol-based polymers for reducing deposition of organic contaminants in papermaking processes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3962259A (en) * | 1973-12-12 | 1976-06-08 | American Hoechst Corporation | 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof |
| NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| CA2226058C (en) * | 1997-01-30 | 2008-01-29 | F. Hoffmann-La Roche Ag | 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives |
-
1998
- 1998-11-20 US US09/196,992 patent/US6166209A/en not_active Expired - Fee Related
- 1998-12-03 ES ES98965753T patent/ES2229557T3/es not_active Expired - Lifetime
- 1998-12-03 CA CA002310458A patent/CA2310458C/en not_active Expired - Fee Related
- 1998-12-03 DE DE69826891T patent/DE69826891T2/de not_active Expired - Lifetime
- 1998-12-03 EP EP98965753A patent/EP1037892B1/en not_active Expired - Lifetime
- 1998-12-03 AT AT98965753T patent/ATE278695T1/de not_active IP Right Cessation
- 1998-12-03 KR KR10-2000-7006304A patent/KR100369689B1/ko not_active IP Right Cessation
- 1998-12-03 AU AU21578/99A patent/AU744192B2/en not_active Ceased
- 1998-12-03 TR TR2000/01669T patent/TR200001669T2/xx unknown
- 1998-12-03 CN CN98812049A patent/CN1112365C/zh not_active Expired - Fee Related
- 1998-12-03 PT PT98965753T patent/PT1037892E/pt unknown
- 1998-12-03 WO PCT/EP1998/007864 patent/WO1999029696A1/en active IP Right Grant
- 1998-12-03 JP JP2000524289A patent/JP3453121B2/ja not_active Expired - Lifetime
- 1998-12-03 BR BR9813543-0A patent/BR9813543A/pt not_active Application Discontinuation
- 1998-12-09 AR ARP980106249A patent/AR016431A1/es unknown
- 1998-12-10 ZA ZA9811345A patent/ZA9811345B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR200001669T2 (tr) | 2001-01-22 |
| CN1281459A (zh) | 2001-01-24 |
| BR9813543A (pt) | 2000-10-10 |
| AU2157899A (en) | 1999-06-28 |
| EP1037892B1 (en) | 2004-10-06 |
| ATE278695T1 (de) | 2004-10-15 |
| CN1112365C (zh) | 2003-06-25 |
| KR100369689B1 (ko) | 2003-01-30 |
| CA2310458A1 (en) | 1999-06-17 |
| CA2310458C (en) | 2008-11-04 |
| DE69826891D1 (de) | 2004-11-11 |
| US6166209A (en) | 2000-12-26 |
| PT1037892E (pt) | 2005-01-31 |
| ES2229557T3 (es) | 2005-04-16 |
| DE69826891T2 (de) | 2005-11-24 |
| AU744192B2 (en) | 2002-02-21 |
| ZA9811345B (en) | 1999-06-11 |
| KR20010032958A (ko) | 2001-04-25 |
| JP2001525414A (ja) | 2001-12-11 |
| WO1999029696A1 (en) | 1999-06-17 |
| EP1037892A1 (en) | 2000-09-27 |
| JP3453121B2 (ja) | 2003-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016431A1 (es) | Derivados de piperidina, un proceso para su preparacion, medicamentos que los comprenden y el uso de dichos derivados para la manufactura de un medicamento | |
| SE0104334D0 (sv) | Therapeutic agents | |
| BR9500996A (pt) | Derivado de difenila,agente terapêutico,processo para a preparação de um derivado de difenila,derivado de fenilpiperazina,composição farmacológica e métodos para fazer um medicamento e para tratar ou melhorar uma doença | |
| BR0312216A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito que sofre de uma doença ou condição patológica e combinação de produto | |
| EP0771563B1 (en) | Use of 5-HT1A receptor ligands for the treatment of glaucoma | |
| FR2742149B1 (fr) | Nouveaux derives de 2-naphtamides et leurs applications therapeutiques | |
| BR9805297A (pt) | Derivados de 1,3,8-triazaspiro (4,5) decan-4on. | |
| JPH01501226A (ja) | 化学療法剤によってひきおこされた▲おう▼吐のコントロール方法およびそれに有用な鎮吐薬 | |
| ES2157201T3 (es) | Derivados carbamato de 4-amino-3-isoxazolidinonas y 3-amino-1-hidroxipirrolidin-2-onas, un procedimiento para su preparacion y su uso como medicamentos. | |
| AR038704A1 (es) | Derivados de tiazol como antagonistas del receptor nyp | |
| IT1317048B1 (it) | Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie | |
| KR940003953A (ko) | 1. 4-벤조디옥산 유도체 | |
| BRPI0618971A2 (pt) | compostos derivados de isoqionolina e benzo [h] isoqionolina, composição farmacêutica, utilização dos compostos e processo de preparo dos compostos | |
| AR012737A1 (es) | Derivados de triptolida utiles en el tratamiento de las enfermedades autoinmunes y usos en la fabricacion de medicamentos | |
| BR9913106A (pt) | Derivados de piperidina | |
| IL43820A (en) | Pharmacological preparations for the treatment of deformed disabled, containing symptomatic aminophytic bronchodilators | |
| PT99864A (pt) | Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato | |
| PL97347B1 (pl) | Sposob wytwarzania nowych 2-fenylohydrazyno-tiazolin lub-tiazyn | |
| KR100407399B1 (ko) | 세로토닌 ｎ-아세틸트란스퍼라제의 활성 억제제 | |
| JP3992156B2 (ja) | 鎮痛特性を有する新規のｎ−アセチル化４−ヒドロキシフェニルアミン誘導体及びそれを含む薬理組成物 | |
| ES2088567T3 (es) | Empleo de derivados de la 2-iminotioazolidin-4-ona como nuevos productos activos para medicamentos. | |
| JP2023510865A (ja) | 血管脂肪腫の処置のための組成物 | |
| JPH037229A (ja) | 脳神経機能改善剤 | |
| AR043003A1 (es) | Compuestos (benzoimidazol-2-il) fenilaminas n-sustituidas, procedimiento para su preparacion, su uso como farmacos o como ayuda en diagnostico, y los medicamentos que las contienen | |
| NO970431L (no) | Tetrahydroisokinolin-derivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |